Clinical Trial Update: Nivolumab/Ipilimumab in Second Line CUP-syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nivolumab/ipilimumab in second-line cancer of unknown primary site.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary Site

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Cancer of Unknown Primary Site | Phase 2 | Status: UNKNOWN